In support of Governor Andrew M. Cuomo’s innovation-driven economic development strategy, the Governor’s Office, New York State Department of Labor, and College of Nanoscale Science and Engineering (CNSE) of the University at Albany will partner to host a Nano Job Fair on Saturday, February 2 at CNSE’s Albany NanoTech Complex, with targeted outreach now underway to attract qualified women, veterans and minority candidates to help fill more than 300 current and future openings at CNSE, including positions with the Global 450mm Wafer Consortium (G450C).
Veeco Instruments Inc. announced today that the University of Waterloo, located at the heart of Canada’s technology hub, has purchased a GEN10® Molecular Beam Epitaxy system for its recently opened Quantum-Nano Centre (QNC) hosting the Waterloo Institute for Nanotechnology (WIN) and the Institute for Quantum Computing (IQC). The system will be installed in the new MBE laboratory being established by Professor Zbig Wasilewski, Endowed Nanotechnology Chair at WIN.
Nano Labs Corp. is an emerging research and development company that is focused on becoming one of the global market leaders in the field of nanotechnology.
Liquipel LLC, the industry leader in Watersafe™ technology, and entrepreneur Pharrell Williams, in conjunction with William Morris Endeavor (WME), today announced a partnership to cross-promote each other's brands and lines of business. Details of the partnership were formally announced at 2 p.m., Jan. 9, at Liquipel's booth, No. 25936, South Hall, at the International Consumer Electronics Show (CES) in Las Vegas, Nev.
Debiopharm Group™ (Debiopharm) and Spinomix SA, a Swiss company advancing molecular diagnostic technologies, announced the closing of a Series A equity investment of $ 3 Million. The financing round was led by Debiopharm Group™.
Reportlinker.com announces that a new market research report is available in its catalogue: A Magnetic Moment: Prospects for MRAM Technology, Markets and Applications
NanoViricides, Inc. (the "Company") announced today that it has retained Id3A, LLC (“Id3A”), as the architect for its laboratory and cGMP pilot production facility project. As previously announced, this facility will be built by renovating an existing 18,000 sq. ft. light manufacturing plant on a 4.2 acre lot in Shelton, CT. Ms. Kathyann Cowles, AIA, will serve as the Principal Architect for the project. Id3A recently began working with the Company for the architecture portion and now the Company has formally engaged Id3A as the architects for this project.
NanoViricides, Inc. (the "Company"), announced today that it has received the final tranche of $2.5M from Seaside 88, LP (“Seaside”), thereby completing the total of a $5M financing. This raise, and the receipt of the initial $2.5M tranche, was previously announced on June 29, 2012.
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases, announced today that it has secured a $16 million Series B financing. Blend is pioneering an integrative model for discovering novel molecular entities with new mechanisms of action purposely designed for Blend’s proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together, Blend can make medicines more targeted, more effective and more tolerable.
Applied DNA Sciences, Inc., (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today that the UK Metropolitan Police Service (MPS) will be using its proprietary DNANet™ property marking kits as part of a major initiative to reduce crime in targeted London neighborhoods.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.